COVID variants throw J&J vaccine a curveball, lowering efficacy to 66%
The adenovirus vector-based vaccine is another useful tool against SARS-CoV-2.
Full Article
COVID variants throw J&J vaccine a curveball, lowering efficacy to 66%
Ars Technica
0 shares
1 views
You might like
Related news coverage
New Surge Spreads In The U.S. As Third Vaccine Is Within Reach
Newsy
Watch VideoThe list of states reporting new infections from a highly-contagious coronavirus variant is growing...
"Not..
Advertisement
More coverage
Data Inconclusive on Efficacy of Moderna Vaccine Against COVID-19 Variants
VOA News
More clinical evidence is needed to know whether the two-dose regimen of the vaccine protects against the coronavirus variants,..